Protalix BioTherapeutics Stock (AMEX:PLX), Analyst Ratings, Price Targets, Predictions

The latest price target for Protalix BioTherapeutics (AMEX: PLX) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $10.00 expecting PLX to rise to within 12 months (a possible 777.19% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Protalix BioTherapeutics (AMEX: PLX) was provided by HC Wainwright & Co., and Protalix BioTherapeutics reiterated their buy rating.

There is no last upgrade for Protalix BioTherapeutics.

There is no last downgrade for Protalix BioTherapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protalix BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protalix BioTherapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.

While ratings are subjective and will change, the latest Protalix BioTherapeutics (PLX) rating was a reiterated with a price target of $0.00 to $10.00. The current price Protalix BioTherapeutics (PLX) is trading at is $1.14, which is within the analyst’s predicted range.